Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO

Executive Summary

With three new approvals in January, the first anticancer about to be authorized, and a vote of confidence from the oncology physicians’ body ESMO, the European biosimilar medicines sector already seems to be picking up momentum in 2017.


Related Content

Celltrion's Truxima First Biosimilar MAB In Oncology To Win EU Approval
‘Non-Medical Switching’ Claim Riles Europe’s Biosimilars Industry
Biosimilar Firms Say Irish Price Deal Hinders Uptake, As Govt Plans New Policy Measures
Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU
First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn
Italy To Relax Biosimilar Switching Rules In Cost-Savings Effort
Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study


Related Companies